Trial reportEuropean journal of nuclear medicine and molecular imaging2021
COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome.
Trial report in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Lung Inflammation With FDG PET/CT in COVID-19
Evaluation of COVID-19 by Whole-body FDG-PET/CT
Who cites it
38 citing papers in PubMed, 57 citations in OpenAlex.
- Contribution ofCurrent issues in molecular biology · 2025Review
- Role ofTranslational cancer research · 2025Article
- Post-COVID-19 lung disease: utility of biochemical and imaging markers in uncovering residual lung inflammation and monitoring anti-inflammatory therapy, a prospective study.European journal of nuclear medicine and molecular imaging · 2025Article
- Genomic insight into COVID-19 severity in MAFLD patients: a single-center prospective cohort study.Frontiers in genetics · 2024Article
- Total-Body Multiparametric PET Quantification ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- The effect of COVID-19 on nuclear medicine and radiopharmacy activities: A global survey.Scientific reports · 2023Article
- Longitudinal analyses usingAntiviral research · 2023Article
- Post-COVID-19 Brain [AJNR. American journal of neuroradiology · 2023Article
- Review
- The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence.Viruses · 2023Review
- Total-Body Multiparametric PET Quantification ofmedRxiv : the preprint server for health sciences · 2023Article
- [Clinical and translational imaging · 2023Article
- The Clinical Utility of Molecular Imaging in COVID-19: An Update.Seminars in nuclear medicine · 2023Review
- The value of FDG-PET/CT imaging in the assessment, monitoring, and management of COVID-19.European physical journal plus · 2023Review
- Mechanisms of coronavirus infectious disease 2019-related neurologic diseases.Current opinion in neurology · 2022Review
- Computed tomography and [iScience · 2022Article
- [Diagnostics (Basel, Switzerland) · 2022Article
- A case-control evaluation of pulmonary and extrapulmonary findings of incidental asymptomatic COVID-19 infection on FDG PET-CT.The British journal of radiology · 2022Article
- Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data.Frontiers in medicine · 2022Review
- FDG-PET/CT of COVID-19 and Other Lung Infections.Seminars in nuclear medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19.
methodsPatients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients' profiles were classified as "inflammatory" or "low inflammatory." FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism.
resultsThirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome.
conclusionInflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs.
trial registrationNCT04441489. Registered 22 June 2020 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.